Triethylenetetramine pharmacology and its clinical applications

Molecular Cancer Therapeutics

Volumn 9, Issue 9, 2010, Pages 2458-2467

  Lu, Jun ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACYL CARRIER PROTEIN ACETYLTRANSFERASE; FUROSEMIDE; SPERMIDINE; SPERMINE; TRIENTINE;

ACETYLATION; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; COLITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; HUMAN; IRON DEFICIENCY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; PARESTHESIA; PRIORITY JOURNAL; RASH; REVIEW; SIDEROBLASTIC ANEMIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; WILSON DISEASE;

ANIMALS; CHELATING AGENTS; HEPATOLENTICULAR DEGENERATION; HUMANS; TRIENTINE;

EID: 77956595942     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0523     Document Type: Review

References (97)

1. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1:643-7.
2. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295-507.
3. Walshe JM. Orphan drugs: food for thought. In: Scheinberg IH, Walshe JM, editors. Orphan diseases and orphan drugs. Manchester: Manchester University Press in Association with the Fulbright Commission; 1986, p. 1-5.
4. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007;369:397-408.
5. Cooper GJ, Phillips AR, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004;53:2501-8.
6. Cooper GJ, Chan YK, Dissanayake AM, et al. Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 2005;54:1468-76.
7. Cooper GJ, Young AA, Gamble GD, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia 2009;52:715-22.
8. Liu J, Guo L, Yin F, Zheng X, Chen G, Wang Y. Characterization and antitumor activity of triethylene tetramine, a novel telomerase inhibitor. Biomed Pharmacother 2008;62:480-5.
9. Yoshii J, Yoshiji H, Kuriyama S, et al. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 2001;94:768-73.
10. Yoshiji H, Yoshii J, Kuriyama S, et al. Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice. Oncol Rep 2005;14:213-8.
11. Moriguchi M, Nakajima T, Kimura H, et al. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 2002;102:445-52.
12. Brown DPG, Chin-Sinex H, Nie B, Mendonca MS, Wang M. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol 2009;63:723-30.
13. Kadowaki S, Endoh D, Okui T, Hayashi M. Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells by activation of the p38 MAPK pathway. J Vet Med Sci 2009;71:1541-4.
14. Leggio L, Addolorato G, Abenavoli L, Gasbarrini G. Wilson's disease: clinical, genetic and pharmacological findings. Int J Immunopathol Pharmacol 2005;18:7-14.
15. Dixon HBF. The chemistry of trientine. In: Scheinberg IH, Walshe JM, editors. Orphan diseases and orphan drugs. Manchester: Manchester University Press in Association with the Fulbright Commission; 1986, p. 23-32.
16. Taylor RM, Chen Y, Dhawan A, EuroWilson Consortium. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. Eur J Pediatr 2009;168:1061-8.
17. Wichmann KA, Boyd PDW, Söhnel T, Allen GR, Phillips ARJ, Cooper GJS. Characterization of dicarboxylic salts of protonated triethylenetetramine useful for the treatment of copper-related pathologies. Cryst Growth Des 2007;7:1844-50.
18. Seiler N. Use of the dansyl reaction in biochemical analysis. Methods Biochem Anal 1970;18:259-337.
19. Zai ES. Approaches to the assay of trientine dihydrochloride. Anal Proc 1982;19:125-6.
20. Miyazaki K, Kishino S, Kobayashi M, Arashima S, Matsumoto S, Arita T. Determination of triethylenetetramine in plasma of patients by high-performance liquid chromatography. Chem Pharm Bull (Tokyo) 1990;38:1035-8.
21. Maemura S, Matsuzaki Y, Asano T, et al. Maximum tolerated dose and repeated dose toxicity studies of triethylenetetramine dihydrochloride, a copper chelating agent, by oral administration to beagle dogs. Yakuri to Chiryo - Japan Pharmacology & Therapeutics 1998;26:745-67.
22. Nakano Y, Nohta H, Yoshida H, et al. Liquid chromatographic determination of triethylenetetramine in human and rabbit sera based on intramolecular excimer-forming fluorescence derivatization. J Chromatogr B Analyt Technol Biomed Life Sci 2002;774:165-72.
23. Othman A, Lu J, Sunderland T, Cooper GJS. Development and validation of a rapid HPLC method for the simultaneous determination of triethylenetetramine and its two main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2007;860:42-8.
24. Nohta H, Satozono H, Koiso K, Yoshida H, Ishida J, Yamaguchi M. Highly selective fluorometric determination of polyamines based on intramolecular excimer-forming derivatization with a pyrene-labeling reagent. Anal Chem 2000;72:4199-204.
25. Kodama H, Meguro Y, Tsunakawa A, Nakazato Y, Abe T, Murakita H. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson's disease. Tohoku J Exp Med 1993;169:59-66.
26. Hansen EB, Jr., Rushing LG, Thompson HC, Jr. Determination of triethylenetetramine dihydrochloride in aqueous solution by reversed-phase ion-pairing high performance liquid chromatography and conductivity detection. J Anal Toxicol 1985;9:167-71.
27. Lu J, Chan Y-K, Poppitt SD, Cooper GJS. Determination of triethylenetetramine (TETA) and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry (LC-MS). J Chromatogr B Analyt Technol Biomed Life Sci 2007;859:62-8.
28. Gibbs KR, Walshe JM. The metabolism of trientine: animal studies. In: Scheinberg IH, Walshe JM, editors. Orphan diseases and orphan drugs. Manchester: Manchester University Press in Association with the Fulbright Commission; 1986, p. 33-42.
29. Iseki K, Kobayashi M, Ohba A, et al. Comparison of disposition behavior and de-coppering effect of triethylenetetramine in animal model for Wilson's disease (Long-Evans Cinnamon rat) with normal Wistar rat. Biopharm Drug Dispos 1992;13:273-83.
30. Kobayashi M, Sugawara M, Saitoh H, Iseki K, Miyazaki K. Intestinal absorption and urinary excretion of triethylenetetramine for Wilson's disease in rat. Yakugaku Zasshi 1990;110:759-63.
31. Tanabe R. Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilson's disease. Hokkaido Igaku Zasshi 1996;71:217-28.
32. Takeda S, Ono E, Matsuzaki Y, et al. Metabolic fate of triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250) 3. Bioavailability of TJA-250 in rats after single administration. Oyo Yakuri - Applied Pharmacology 1995;49:179-86.
33. 14C-TJA-250. Oyo Yakuri - Applied Pharmacology 1995;49:173-8.
34. 14C-TJA-250. Oyo Yakuri - Applied Pharmacology 1995;49:163-71.
35. Meguro Y, Kodama H, Nakazato Y, Abe T. Detection of triethylenetetramine dihydrochloride in serum and urine samples. Biomed Res Trace Elem 1991;2:131-2.
36. Murata Y, Hase M, Tsunakawa A, Kodama H, Abe T. Identification of metabolite of triethylene tetramine (Trien), a therapeutic drug of Wilson's Disease. Biomed Res Trace Elem 1993;4:185-6.
37. Kodama H, Murata Y, Iitsuka T, Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci 1997;61:899-907.
38. Lu J, Chan Y-K, Gamble GD, Poppitt SD, Cooper GJS. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type-2 diabetic patients. Drug Metab Dispos 2007;35:221-7.
39. Cho H-Y, Blum RA, Sunderland T, Cooper GJS, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. J Clin Pharmacol 2009;49:916-28.
40. Lu J, Poppitt SD, Othman AA, et al. Pharmacokinetics, Pharmacodynamics and Metabolism of Triethylenetetramine in Healthy Human Participants: An Open Label Trial. J Clin Pharmacol 2010;50:647-58.
41. Kobayashi M, Nagahara S, Sugawara M, et al. Serum concentration and urinary excretion of Trientine in patients with Wilson's Disease. TDM Kenyu - TDM Research 1993;10:166-71.
42. Tanabe R, Kobayashi M, Sugawara M, Iseki K, Miyazaki K. Uptake mechanism of trientine by rat intestinal brush-border membrane vesicles. J Pharm Pharmacol 1996;48:517-21.
43. Kobayashi M. The transport mechanism of polycationic compounds across intestinal and renal cell membrane. Yakugaku Zasshi 2002;122:607-14.
44. Belting M, Mani K, Jonsson M, et al. Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivotal role for nitrosothiol-derived nitric oxide. J Biol Chem 2003;278:47181-9.
45. Toninello A, Dalla Via L, Siliprandi D, Garlid KD. Evidence that spermine, spermidine, and putrescine are transported electrophoretically in mitochondria by a specific polyamine uniporter. J Biol Chem 1992;267:18393-7.
46. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36:205-16.
47. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Curr Drug Targets 2003;4:565-85.
48. Kobayashi M, Tanabe R, Sugawara M, Iseki K, Miyazaki K. The mechanism of excretion of trientine from the rat kidney: trientine is not recognized by the H+/organic cation transporter. J Pharm Pharmacol 1997;49:426-9.
49. Kobayashi M, Fujisaki H, Sugawara M, Iseki K, Miyazaki K. The presence of an Na+/spermine antiporter in the rat renal brush-border membrane. J Pharm Pharmacol 1999;51:279-84.
50. Lee SH, Yang YJ, Kim KM, Chung BC. Altered urinary profiles of polyamines and endogenous steroids in patients with benign cervical disease and cervical cancer. Cancer Lett 2003;201:121-31.
51. Russell DH, Levy CC, Schimpff SC, Hawk IA. Urinary polyamines in cancer patients. Cancer Res 1971;31:1555-8.
52. Brewer GJ, Yuzbasiyan-Gurkan V, Young AB. Treatment of Wilson's disease. Semin Neurol 1987;7:209-20.
53. Kobayashi M, Fujisaki H, Sugawara M, Iseki K, Miyazaki K. Effects of interactions between drugs on the renal excretion of trientine in rats-acetazolamide and furosemide increase trientine excretion. Pharm Res 1999;16:1888-92.
54. Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 1987;317:209-13.
55. Dubois RS, Rodgerson DO, Hambidge KM. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine). J Pediatr Gastroenterol Nutr 1990;10:77-81.
56. Saito H, Watanabe K, Sahara M, Mochizuki R, Edo K, Ohyama Y. Triethylene-tetramine (trien) therapy for Wilson's disease. Tohoku J Exp Med 1991;164:29-35.
57. Siegemund R, Lossner J, Gunther K, Kuhn HJ, Bachmann H. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease. Acta Neurol Scand 1991;83:364-6.
58. Morita J, Yoshino M, Watari H, et al. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations. Dev Pharmacol Ther 1992;19:6-9.
59. Condamine L, Hermine O, Alvin P, Levine M, Rey C, Courtecuisse V. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993;83:166-8.
60. Dahlman T, Hartvig P, Lofholm M, Nordlinder H, Loof L, Westermark K. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). QJM 1995;88:609-16.
61. Perry AR, Pagliuca A, Fitzsimons EJ, Mufti GJ, Williams R. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996;64:69-72.
62. Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003;142:385-90.
63. Kumagi T, Horiike N, Michitaka K, et al. Recent clinical features of Wilson's disease with hepatic presentation. J Gastroenterol 2004;39:1165-9.
64. Brewer GJ, Askari F, Dick RB, et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 2009;154:70-7.
65. Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006;63:521-7.
66. Arnon R, Calderon JF, Schilsky M, Emre S, Shneider BL. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J Pediatr Gastroenterol Nutr 2007;44:596-602.
67. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007;56:115-20.
68. Walshe JM. The management of pregnancy in Wilson's disease treated with trientine. QJM 1986;58:81-7.
69. Nunns D, Hawthorne B, Goulding P, Maresh M. Wilson's disease in pregnancy. Eur J Obstet Gynecol Reprod Biol 1995;62:141-3.
70. Devesa R, Alvarez A, de las Heras G, Ramon de Miguel J. Wilson's disease treated with trientine during pregnancy. J Pediatr Gastroenterol Nutr 1995;20:102-3.
71. Walshe JM. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. QJM 1973;42:441-52.
72. Lixia G, Fei Y, Jiajia J, Jianhui L. Triethylene tetramine, a novel ligand of G-quadruplex, induces senescence of MCF-7 cells. Biotechnol Lett 2008;30:47-53.
73. Yin F, Liu J, Peng X. Triethylene tetraamine: a novel telomerase inhibitor. Bioorg Med Chem Lett 2003;13:3923-6.
74. Yin F, Liu J, Peng X. Effects of triethylene tetraamine on telomerase activity and proliferation in HeLa cells. Cell Biol Int 2004;28:287-91.
75. Yin F, Liu J, Deng X, Wang J. Effects of triethylene tetraamine on the G-quadruplex structure in the human c-myc promoter. J Biochem 2007;141:669-74.
76. Harris ED. A requirement for copper in angiogenesis. Nutr Rev 2004;62:60-4.
77. Yoshiji H, Kuriyama S, Yoshii J, et al. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression. Oncol Rep 2003;10:1369-73.
78. Sproull M, Brechbiel M, Camphausen K. Antiangiogenic therapy through copper chelation. Expert Opin Ther Targets 2003;7:405-9.
79. Camphausen K, Sproull M, Tantama S, et al. Evaluation of chelating agents as anti-angiogenic therapy through copper chelation. Bioorg Med Chem 2004;12:5133-40.
80. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 2006;12:6876-83.
81. Lombardo MF, Ciriolo MR, Rotilio G, Rossi L. Prolonged copper depletion induces expression of antioxidants and triggers apoptosis in SH-SY5Y neuroblastoma cells. Cell Mol Life Sci 2003;60:1733-43.
82. Baynes JW, Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diabetes Res 2009;2009:696378.
83. Gong D, Lu J, Chen X, et al. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats. Mol Pharmacol 2006;70:2045-51.
84. Lu J, Gong D, Choong SY, et al. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 2010;53:1217-26.
85. Gong D, Lu J, Chen X, et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia 2008;51:1741-51.
86. Hamada Y, Nakashima E, Naruse K, et al. A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. J Diabetes Complications 2005;19:328-34.
87. Cui JZ, Wang X-F, Hsu L, Matsubara JA. Inflammation induced by photocoagulation laser is minimized by copper chelators. Lasers Med Sci 2009;24:653-7.
88. Walshe JM. Cause of death in Wilson disease. Mov Disord 2007;22:2216-20.
89. Schilsky ML. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation? Curr Gastroenterol Rep 2001;3:54-9.
90. Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord 2008;23:768-70.
91. Fukuda H, Ebara M, Okabe S, et al. Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. J Lab Clin Med 2004;143:333-9.
92. Nagano S, Fujii Y, Yamamoto T, et al. The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol 2003;179:176-80.
93. Cherny RA, Barnham KJ, Lynch T, et al. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol 2000;130:209-16.
94. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10.
95. Pass HI, Brewer GJ, Dick R, et al. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008;86:383-9.
96. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-72.
97. Seiler N. Pharmacological aspects of cytotoxic polyamine analogs and derivatives for cancer therapy. Pharmacol Ther 2005;107:99-119.